EGFR and non-small cell lung carcinoma: Additionally, due to the heterogeneity of tumors, wild epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) promotes the resistance of mutated EGFR NSCLC to osimertinib by transferring wild EGFR to mutant NSCLC [154].